A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang, S Hirawat, G Laird, D Johnson, HM Prince